Challenges in ATTR Amyloidosis: An Expert Debate
Published: 20 May 2024
-
Views:
11300
-
Likes:
7
-
Views:
11300
-
Likes:
7
-
Up Next
-
2m 32sPart 1 Welcome and Introduction Thibaud Damy, Ahmad Masri, Esther González López, João R Agostinho
-
19m 8sPart 2 Identifying ATTR in a Regular Cardiac Clinic Thibaud Damy, Esther González López, João R Agostinho, Ahmad Masri
-
16m 41sPart 3 Managing Patients with a Mixed Phenotype Thibaud Damy, Esther González López, João R Agostinho, Ahmad Masri
-
16m 49sPart 4 Disease Modifying Treatment for ATTR-CM Ahmad Masri, Thibaud Damy, Esther González López, João R Agostinho
Overview
Radcliffe Medical Education bring together a globally-renowed faculty, including Prof Thibaud Damy (Creteil, FR) as he chairs a panel of distinguished experts, Dr Esther González López (Madrid, SP), Dr João R. Agostinho (Lisbon, PT) and Dr Ahmad Masri (Portland, USA) in a interactive symposium centred around three distinctive challenges facing physicians when diagnosing and treating ATTR-CM patients.
During this session, the panel discuss key challenges in ATTR Amyloidosis including identifying ATTR in regular cardiac clinic, managing patients with a mixed phenotype and disease modifying treating for ATTR-CM.
This Satellite Symposium was supported by an unrestricted educational grant from AstraZeneca who had no involvement in the content.
Presented, and recorded, at HFA 2024 in Lisbon, PT
Note, this on-demand video series is not accredited, if you would like to gain accreditation from this programme, please follow the link here.
Key Learning Objectives
- Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis.
- Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance.
- Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype.
- Recall the limitations of existing therapies for ATTR-CM.
- List the advantages of emerging classes of agents being evaluated in ATTR-CM.
Target Audience
- Heart Failure Specialists
- Cardiac Amyloidosis Specialists
- Echocardiologists
More from this programme
Part 1
Welcome and Introduction
Thibaud Damy introduces this inaugural session by introducing the faculy, reviewing the educational learning objectives and launching the first audience poll.
| 1 session | |
| Welcome and Introduction | Watch now |
Part 2
Identifying ATTR in a Regular Cardiac Clinic
In this session, Dr Esther González López presents the first challenge and highlights on missed diagnosis in general cardiology and heart failure care.
Part 3
Managing Patients with a Mixed Phenotype
During Challenge 2, João R. Agostinho discusses the number of patients with a mixed phenotype and considerations that need to be taken for long-term management.
Part 4
Disease Modifying Treatment for ATTR-CM
In this final challenge, Dr Ahmad Masri presents on the limitations with current stabilisers in ATTR-CM, and CM outcomes from silencer agents evaluation in PN patients.
Part 5
Closing Remarks
Thibaud Damy re-launches the same poll question and discusses changes in answers made by the live audience.
| 1 session | |
| Closing Remarks | Watch now |
Faculty Biographies
Thibaud Damy
Professor Thibaud Damy is a cardiologist focusing on heart failure and cardiac amyloidosis. He works at Hospital Henri Mondor and Paris East Creteil University (UPEC), and is part of INSERM U955. Prof Damy leads the Referral Center for Cardiac Amyloidosis and the French National Amyloidosis Network, which includes a registry of about 4,500 patients.
Ahmad Masri
Dr Ahmad Masri M.D., M.S. trained in Internal Medicine at the Cleveland Clinic.
He specialises in caring for patients with conditions that result in abnormally thickened hearts, such as hypertrophic cardiomyopathy, amyloidosis and Fabry’s disease.
Esther González López
Dr. Gonzalez-Lopez trained in Cardiology at Hospital Puerta de Hierro Majadahonda (HUPHM) in Madrid, where she completed her doctoral thesis on imaging techniques in transthyretin cardiac amyloidosis. Her work, including the acclaimed paper "Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction" (Eur Heart J. 2015), won the Dr. Cardeñosa Research Prize in 2015. She has also conducted research at CNIC in Madrid, Brigham and Women's Hospital in Boston, and worked as a Consultant Cardiologist at the National Amyloidosis Centre in London. Currently, she is at HUPHM, supported by a Juan Rodés grant, focusing on cardiac imaging and inherited cardiac diseases, especially transthyretin cardiac amyloidosis.
João R Agostinho
Dr João R. Agostinho is a prominent cardiologist and researcher based in Lisbon, Portugal. He is affiliated with several esteemed institutions, including the Hospital Universitário de Santa Maria, the Centro Hospitalar Universitário de Lisboa Norte (CHULN), and the Lisbon School of Medicine at the Universidade de Lisboa.
Dr Agostinho has a strong focus on cardiology, having served as a graduate teaching assistant in cardiology since 2012 and in introduction to clinical medicine since 2010.
Comments